FV Pharma Inc.

(anticipated ticker "HUGE" upon completion of Go Public Transaction)

EXCLUSIVE GO PUBLIC OFFERING

$18 MILLION AT $0.09 PER Subscription Receipt

CLOSES LATEST January 31, 2018

BOOKS MAY CLOSE ANY TIME

All Submissions must be made by E-Mail to This email address is being protected from spambots. You need JavaScript enabled to view it.

FV Pharma’s management mission is to make the former Kraft plant in Cobourg the largest hydroponic cannabis indoor facility in the world.

 It is only 1 hour drive east of Toronto on the 401 highway.

Received ACMPR License from Health Canada

Phase 1 Expansion Target:

Total - 820,000 sq.ft. 

Phase 2 Expansion Target:

Total - 3,896,000 sq.ft. 

FV Pharma owns 70-acre parcel of land DEBT FREE

27 acre – Plant

5 acre – Parking Lot

38 acre – Expansion Land

Signed letter of intent (LOI) for RTO with Century Financial Capital Group Inc. (To be renamed Cannabis ConneXion Inc.). Click here to read Press Release

All under one roof to promote lower cost and economies of scale

FV Pharma Objectives

• Modelling its business plan after big pharma companies
• Focusing on tight cost controls and economies of scale

Electrical substation on site

Can power over 9,000 x 1,000 watt grow bulbs

Distributed in a bank of 3 independent subs of 13800 KVA each

Multiple natural gas lines on site

26 Loading docks

Food grade facility built to better deal with bug problems

FV Pharma News: Joint Venture with Cannabis Wheaton (TSXV: CBW)

• FV Pharma to receive 50.1% and CBW to receive 49.9% of all cannabis produced under CBW
• CBW Believes that this will result in approximately 200,000,000 grams of Cannabis per annum for each company's benefit once the facility is fully built out and operational
• Chuck Rifici, CEO of CBW and co-founder of Tweed (Now Canopy Growth), to bring Operational Management Expertise in:
  • Design
  • Development
  • Financing
  • Grow Operations

Click Here to View CBC Interview with Chuck Rifici

Management

Thomas Fairfull, President & CEO

Thomas Fairfull has extensive experience in guiding companies through the process of developing, testing and commercializing products and consulting with companies bringing innovative products to market. In 2001, Mr. Fairfull founded Dynacert (TSXV:DYA) which specialized in on-board hydrogen generation technology, which is currently being used by PepsiCo. Dynacert (TSXV:DYA) was the most actively traded TSXV stock in 2016. In 2004, he successfully raised in excess of $20 million in private equity and subsequently took the company public in a successful initial public offering (IPO) and became President and CEO of a TSX Venture Exchange-traded corporation. 

Financing

Issue Price per Subscription Receipt:

$0.09 per Subscription Receipt.

Total Offering Size:

Up to $18,000,000

Capital Structure:

15,000 Class “A” Common Voting Shares are issued and outstanding

763,462,145 Class “B” Common Non-Voting Shares are issued and outstanding

No Debt

Use of Proceeds:

To fund working capital and operations of the Company

To list FV Pharma on the CSE

Eligibility:

Accredited Investor Exemption

Friends, Family and Business Associates Exemption

Closing Date:

Closing of this offering is expected to occur latest January 31, 2018

Books may close any time

Subject to cutbacks

Submission:

ALL submissions must be made by E-Mail to This email address is being protected from spambots. You need JavaScript enabled to view it.

**Please be advised that orders will be filled based on a first come first served basis and book may close without notice.**

Best regards,

Anthony Durkacz

First Republic Capital

Executive VP

This email address is being protected from spambots. You need JavaScript enabled to view it.

416 720 4360

Yazeed Esnan

First Republic Capital

Associate

This email address is being protected from spambots. You need JavaScript enabled to view it.

647 533 2124

IMPORTANT NOTICE 1: In connection with the Offering, the Corporation is a “related issuer” and may be considered a ‘‘connected issuer’’ (as such terms are defined in National Instrument 33-105 - Underwriting Conflicts) of the Agent and Anthony J. Durkacz. Mr. Durkacz, the Executive Vice President, Director and majority shareholder of the Agent, is also a control person and thus an “influential security holder” of the Corporation, which creates an inherent conflict of interest. Mr. Durkacz owns shares and warrants to purchase shares of the Corporation, which were purchased prior to the date hereof at a price less than this Offering. For further information, please see Section 9.1 of the Subscription Agreement. 

IMPORTANT NOTICE 2: This message and the information or attachments contained therein is intended only for the use of the individual or entity to which it is addressed. The message may contain information that is confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by return e-mail, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be illegal.